Marie Essig

A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation

Publisher: Future Medicine Ltd

Date: 03-2016

DOI: 10.2217/PGS.15.181

Abstract: Aim: To investigate the potential influence of variants in genes involved in the calcineurin pathway on the efficacy and toxicity of calcineurin inhibitors in renal transplantation. Materials & methods: Twenty-three polymorphisms in thirteen genes were tested in 381 renal transplant recipients receiving ciclosporin (n = 221) or tacrolimus (n = 160) and mycophenolate mofetil. Data were collected prospectively over the first year post-transplantation. Results: Multivariate survival analyses revealed no genetic associations with biopsy proven acute graft rejection and serious infections. Donor–recipient Cytomegalovirus mismatch was the only variable associated with serious infection. Conclusion: This large exploratory study casts doubts on the potential interest of genetic biomarkers related to CNI pharmacodynamics but associations with other phenotypes in transplantation deserve further studies.

The FcγRIIIA‐158 VV genotype increased the risk of post‐transplant lymphoproliferative disorder in T‐cell‐depleted kidney transplant recipients – a retrospective study

Publisher: Frontiers Media SA

Date: 14-05-2020

DOI: 10.1111/TRI.13624

Maribavir Use in Practice for Cytomegalovirus Infection in French Transplantation Centers

Publisher: Elsevier BV

Date: 05-2013

DOI: 10.1016/J.TRANSPROCEED.2013.01.082

Abstract: Maribavir (MBV), a UL97 inhibitor, shows good oral bioavailability, low host cell toxicity, and theoretical benefits to inhibit cross-resistant viruses. We herein examined clinical and virological outcomes of 12 patients, including 3 bone marrow recipients and 9 organ recipients infected with resistant cytomegalovirus (CMV) and treated with MBV during 2011-2012. All received at least 800-mg daily doses. They had developed clinical (12/12) and/or virological (11/12) resistance to CMV infection. Based on a decrease of viral load in blood >1.5 log copies/mL half of them responded to MBV treatment. The in idual changes varied from a rapid decrease in viral load (n = 4) to no response (n = 3) with some late response slowly decreasing viremia (n = 3). In 2 cases MBV was used as secondary prophylaxis. No clear parameter emerged as a clinical surrogate for nonresponse to MBV. These results contrast with the lack of efficacy in phase III trials of MBV prophylaxis among stem cell recipients, which were possibly due to low doses or inadequate timing of drug initiation in the study. Additional clinical and surrogate laboratory markers are needed to determine antiviral responses to guide MBV use. Dosage ranging studies might benefit future MBV use.

Assistance Publique Hôpitaux De Paris

Location: France

View Organisation

University Of Limoges

Location: France

View Organisation

INSERM UMR 1248

Location: France

View Organisation

INSERM 1018

Location: France

View Organisation

Centre Hospitalier Universitaire De Limoges

Location: France

View Organisation

Université Versailles Saint-Quentin-en-Yvelines UFR Simone Veil Santé

Location: France

View Organisation

Université Paris Diderot

Location: France

View Organisation

Université Pierre Et Marie Curie

Location: France

View Organisation